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Substance use disorders (SUDs) remain a significant public health challenge, affecting
tens of millions of individuals worldwide each year. Often comorbid with other psychiatric
disorders, SUD can be poly-drug and involve several different substances including
cocaine, opiates, nicotine, and alcohol. SUD has a strong genetic component. Much
of SUD research has focused on the neurologic and genetic facets of consumption
behavior. There is now interest in the role of the gut microbiome in the pathogenesis
of SUD. In this review, we summarize current animal and clinical evidence that the gut
microbiome is involved in SUD, then address the underlying mechanisms by which the
gut microbiome interacts with SUD through metabolomic, immune, neurological, and
epigenetic mechanisms. Lastly, we discuss methods using various inbred and outbred
mice models to gain an integrative understanding of the microbiome and host genetic
controls in SUD.
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INTRODUCTION
Substance use disorder (SUD) is a mental condition affecting the brain and is characterized in
part by chronic dependence despite negative social, mental, and physical health consequences.
Addiction represents the most severe form of SUD, with affected individuals often incapable of
maintaining abstinence despite the will to discontinue substance use. Importantly, the effects
of addiction can persist beyond cessation of substance use, suggesting that lasting physiological
changes in the brain are involved (Koob et al., 2008). An expansive list of substance classes are
related to SUD, ranging from legal forms, including alcohol, to illicit or controlled forms, including
cocaine and opioids. Alcohol use disorder (AUD) remains the most prevalent SUD, however,
poly-drug use within individuals is not uncommon (Lipari and Van Horn, 2017).
Addictive substances can affect multiple pathways controlling brain function. Alteration of the
dopaminergic system is one common mechanism shared by all substances in the establishment
of recurrent substance use (Nestler, 2005). Notably, substance misuse leads to increased levels
of dopamine release and chronic signal imbalance in D2-like dopamine receptors in the ventral
striatum, particularly in the nucleus accumbens (Koob and Le Moal, 2001; Nestler, 2005). Termed
the mesolimbic pathway, substances of misuse operate to “hijack” the host reward system critical
for pleasurable response and reinforcement to rewarding stimuli, as well as memory and emotional
processes. Furthermore, the chronic use of these substances leads to neuroplasticity and structural
reorganizations, and drug-specific changes in neurotransmitter transporters and receptors (Bliss
et al., 2003; Kauer, 2004). Despite the central role of dopamine in SUD, other neurotransmitters
such as serotonin and gamma-aminobutyric acid (GABA) also play an important role in SUD,
Frontiers in Neuroscience | www.frontiersin.org 1 August 2021 | Volume 15 | Article 725500
fnins-15-725500 August 25, 2021 Time: 17:44 # 2
Russell et al. Microbiome and Substance Use Disorder
depending on the dosage and frequency of substance use,
as well as intrinsic biological factors such as host genetics
(Prom-Wormley et al., 2017).
Previous human linkage studies have shown that children
of individuals affected by SUD are at a greater risk for SUD,
suggesting a genetic component to the risk of developing
the disorder (Kreek et al., 2004). SUD involving cocaine
confers the highest genetic risk of any substance, estimated
at approximately 70% heritability (Goldman et al., 2005).
Numerous genetic loci have been implicated in the heritability
of risk for cocaine SUD, most notably genes involved in
dopamine transport (Drd2, Drd4) and metabolism (Dbh)
(Table 1). AUD also show strong genetic factors with variants
in genes involved in alcohol metabolism (Adh1b, Aldh2) and
diverse variants of smaller effect in dopaminergic systems
(Table 1). However, discordant SUD rates found in identical
twins suggest that genetics alone does not entirely explain
the incidence of SUD (Agrawal and Lynskey, 2008). Aside
from socio-economic factors studied extensively (Stone
et al., 2012), there is intense interest in examining the role
of the gut microbiome in SUD. The gut microbiota are
a diverse population of microorganisms that constantly
interact with the central nervous system (CNS) through
complicated metabolomic, immune, neurological, and epigenetic
pathways, making them potential sources of environmental
influence on SUD.
Although methods for investigating the microbiome in
various diseases have made tremendous advancements in
the last decade (Quigley and Gajula, 2020), studies of SUD
in humans remain challenging because of the difficulty
in controlling for complex experimental variables (for
example, diet and host genotype). Model organisms such
as mice provide excellent opportunities for studying the
microbiome and its interaction with the host due to greater
control over genetic and environmental confounders. In
addition, mice of diverse but known genetic backgrounds
can be harnessed to interrogate complex interactions
between host genotype and the gut microbiota that may
be important for risk of developing SUD (Poltorak et al.,
2018). This review will provide a concise overview of
recent insights on mechanisms of interaction between the
gut microbiota and CNS, in addition to methodological
considerations for studying the gut microbiome in SUD
in animal models.
THE GUT–BRAIN AXIS AND SUBSTANCE
USE
The human gastrointestinal tract is home to a large community
of microbiota on the order of trillions of cells. Likewise,
the collective gene content of the microbiome encodes
a staggering amount of functional potential, with an
estimated 150 times greater number of genes than that
of the human or mouse genome (Grice and Segre, 2012).
Despite a core microbiome, fluctuations in composition
are often observed after administering antibiotics, non-
antibiotic medication, and diet intervention (Caporaso
et al., 2011). This deviation from an individual-defined
normal or “healthy” microbiome in the context of disease
is termed dysbiosis, and a significant body of evidence
has linked the dysbiotic microbiome as a contributor of
disease and recently mental health (Shreiner et al., 2015;
Capuco et al., 2020). There are multiple potential facets
of gut host–microbe interactions to explain these disease
associations, requiring much interdisciplinary research
focus. Emerging evidence suggests prominent roles in
host–microbe immune interaction, crosstalk between the
gut and brain via neurotransmitters, and a role for bacterial
metabolites including short-chain fatty acids (SCFA) in the
pathophysiology of SUD. A summary of representative studies
of the microbiome and SUD in animal models is provided
in Table 2. For a comprehensive summary see the recent
review by Angoa-Pérez and Kuhn (2021).
INTERACTIONS BETWEEN THE
MICROBIOTA AND THE IMMUNE
SYSTEM IN SUD
The gut microbiota produce an immense number of foreign
antigens to which the host immune system must tolerate
under normal homeostasis (Swiatczak and Cohen, 2015).
The intestinal epithelium provides a physical barrier between
the microbiota and immune cells, largely regulating the
immune response to commensal microbes. Evidence suggests
increased intestinal barrier permeability (leaky gut) in SUD,
particularly AUD (Leclercq et al., 2014). Alcohol consumption
has long been associated with developing a leaky gut through
oxidative stress, which allows for increased translocation of
bacterial products into the lamina propria. Here, microbial
antigens can interact directly with gut-localized dendritic cells
and macrophages and upregulate multiple pro-inflammatory
cytokines production, leading to a heightened local and systemic
inflammatory response.
Immune cytokines have modulatory effects on behavior.
Levels of pro-inflammatory cytokines, including IL-1β, TNF-
α, and IL-8, are increased in response to numerous substances
of abuse (Meckel and Kiraly, 2019). Interestingly, this pro-
inflammatory response to substance use is akin to the response
to bacterial lipopolysaccharide (LPS) through signaling via toll-
like receptor 4 (Northcutt et al., 2015). This pro-inflammatory
response further implicates the interaction between the gut
microbiota and the immune system in SUD pathology. It was
observed that alcohol and opiates use leads to an enrichment
of pro-inflammatory Proteobacteria in the gut. Likewise, anti-
inflammatory responses are altered in instances of substance
use which leads to an unbalanced neuroimmune response.
Anti-inflammatory cytokines such as IL-10 have been shown
to modulate and even reverse anxiety behaviors related to
substance use (Patel et al., 2021). Furthermore, IL-10 could
entirely diminish the escalation of alcohol intake by modulating
GABA signaling in the amygdala. Thus, the link between the gut
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TABLE 1 | Substances involved in SUD and addiction, their mechanism of action and genetic risk loci for development of SUD/addiction.
Substance Mechanism of action Risk loci for developing
SUD/addiction
References
Alcohol (ethanol) Acts on multiple targets within
the CNS including GABA
synapse, glutamate signaling,
and other neurotransmitters or









Boileau et al., 2003; Roberto
and Varodayan, 2017;
Edenberg and McClintick,








amphetamines act to stimulate
release of dopamine directly.
Dopamine transport and
metabolism (Drd2, Drd4, Dbh);
norepinephrine transporter
(Slc6a2); 53 B-like family gene
(Fam53b).
Noble et al., 1993; Volkow
et al., 1999; Xu et al., 2000;
Kahlig and Galli, 2003; Avelar
et al., 2013
Opioids (e.g., heroin or
pharmaceutical opioids)
Target the mu-opioid receptor
MOR, leading to the activation
of neurons containing MORs
and subsequent dopamine
release.





Gelernter et al., 2014; Cheng
et al., 2018; Valentino and
Volkow, 2018; Zhou et al., 2020
Nicotine (tobacco) Acts directly on nicotine
receptors leading to dopamine
release, or by activating other
receptors indirectly.
Variants in the cholinergic
nicotinic receptor gene locus
(Chrna1/b1).
D’Souza and Markou, 2011;
Hancock et al., 2018
Cannabis (marijuana) Targets cannabinoid receptor
CB1, indirectly stimulating
dopamine release mediated
through GABA and glutamate.
Variants near the forkhead box
P2 gene (Foxp2); cholinergic
nicotine receptor (Chrna2);
epoxide hydrolase 2 (Ephx2).
Draycott et al., 2014; Demontis
et al., 2019; Johnson et al.,
2020
microbiota and the immune system via neuroimmune pathways
are important research areas in SUD and addiction.
MICROBIOTA-DERIVED
NEUROTRANSMITTERS
Neurotransmitters intuitively play a critical role in the
development and maintenance of all forms of SUD. Numerous
bacteria have been described as capable of producing a number
of neurotransmitters including GABA, serotonin, and dopamine
(Yano et al., 2015; Strandwitz, 2018). A culture study showed
that Bacillus species can produce dopamine. Furthermore,
germ-free and antibiotic-treated mice have shown that the gut
microbiota influences the production and turnover of dopamine
outside the CNS (Strandwitz, 2018). Similar fluctuations in
GABA levels are observed in mice treated with antibiotics
(Yunes et al., 2020). Lactobacillus, Bifidobacteria, and Bacteroides
species were identified to have the capability to produce GABA
(Barrett et al., 2012; Strandwitz et al., 2019). Mice given specific
GABA-producing Lactobacillus or Bifidobacteria have shown
altered behavioral phenotypes (Yunes et al., 2020). Curiously,
neurotransmitters produced by the gut microbiota may not
under normal circumstances directly affect the brain, as whether
these molecules cross the blood–brain barrier is still debated
(Boonstra et al., 2015). However, increasing evidence has shown
that the blood–brain barrier can fluctuate between states of
increased permeability (Braniste et al., 2014). It may also be that
the gut microbiota, rather than producing neurotransmitters
themselves, affect neurotransmitter production or receptor
expression indirectly via signals delivered through the vagus
nerve (Bravo et al., 2011). Studies are ongoing to identify the
full breadth of neurotransmitter-producing strains in the gut
microbiome and the mechanisms by which microbial messages
influence host behavior in the context of SUD.
GUT MICROBIOME MEDIATED
EPIGENETIC MECHANISMS
Substance use leads to changes in gene expression in the brain
in critical signaling pathways in the reward circuitry (Walker
et al., 2018). Regulation of gene activation and repression
is controlled in part epigenetically by adding and removing
histone post-translational modifications. Common modifications
include acetylation and methylation, which work to activate
or silence gene expression, respectively. Importantly, these
modifications are reversible; they can be added or removed
by dedicated enzymes for this process, based on cellular
cues. Histone acetylation, which leads to gene activation by
opening the chromatin structure, increases at the nucleus
accumbens in response to drug use for most substances
(Renthal and Nestler, 2009). Alcohol is a unique case because
the byproduct of ethanol metabolism is acetate itself. Acetate
derived from alcohol metabolism post-consumption is readily
incorporated into the brain, and in mice is associated with spatial
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TABLE 2 | Summary of representative studies using animal models in SUD and microbiome research.
Substance Observations References
Alcohol Antibiotic treatment reduced
voluntary alcohol intake by 70% in
high-drinker rats; vagotomy led to
similar reduction in alcohol
consumption.
Ezquer et al., 2021
Tigecycline antibiotic treatment
reduced ethanol intake in male and
female dependent/non-dependent
C57B/6J mice.
Bergeson et al., 2016
Transplantation of microbiota from
alcohol-fed mice to controls led to
similar alcohol withdrawal-induced
anxiety behavior in recipients.
Xiao et al., 2018
Cocaine Treatment with non-absorbable
antibiotics for 2 weeks led to
behavioral changes (enhanced
reward, sensitization) in response to
cocaine stimulation compared with
controls in male C57BL/6J mice;
microbiota depletion altered
transcriptional activity in the nucleus
accumbens; replacement of SCFAs
reversed the antibiotic effect on
behavior in response to cocaine.
Kiraly et al., 2016
Opioids Intermittent and continuous
treatment with morphine led to
significant changes in the gut
microbiota of male C57BL/6J mice;
Lactobacillus were reduced and
Ruminococcus were enriched after
morphine exposure; antibiotic
treatment led to increased drug
tolerance and alterations in drug
reward behaviors.
Lee et al., 2018
Nicotine Nicotine altered the gut microbiota
of C57BL/6 mice with sex-specific
differences; nicotine led to
decreased weight in males but not
females; oxidative stress and DNA
repair pathways were enriched in
the microbiome after nicotine
treatment; neurotransmitters
(GABA) and precursor metabolites
(glutamate) were significantly
altered by nicotine treatment.
Chi et al., 2017
Cannabis Differential gut microbiota




B6.Cg-Lepob/J) mice linked to
expression of cannabinoid receptor
CB1; modulation of CB1
expression is linked to gut
permeability and leakage of
pro-inflammatory LPS, also
characteristic of the neuroimmune
pathologies observed in SUD.
Muccioli et al., 2010
memory and preference for the rewarding stimulus of alcohol
(Mews et al., 2019). Inhibition or deletion of genes involved
in acetylation, histone acetyltransferase (HAT), and histone
deacetylase (HDAC) leads to alterations in sensitivity and drug-
related behaviors (Cadet, 2016). These lines of evidence implicate
the epigenetics of the brain in chronic SUD and addiction, and
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current research is focusing on the specific genetic loci affected
by epigenetic alteration in response to substance use.
The gut microbiota produces large quantities of SCFAs,
predominantly acetate, propionate, and butyrate, through
carbohydrate metabolism and the breakdown of dietary fiber
(Dalile et al., 2019). Butyrate, a potent HDAC inhibitor,
can modulate host epigenetics through similar pathways as
those affected by substance use (Simon-O’Brien et al., 2015).
The microbial contribution to epigenetic modification may
be important not only for current SUD but also the risk of
developing SUD before initial drug intake, by predisposition
toward the activation of addiction and reward pathways in the
brain (Meckel and Kiraly, 2019).
STUDYING THE MICROBIOME IN SUD
USING INBRED MICE
The use of laboratory rodents to study the neurobiological
aspects of SUD has been well documented, and the use of
animal research to study the environmental effects of the
microbiome is expanding rapidly (Fowler and Kenny, 2012;
Meckel and Kiraly, 2019). Mouse models prove useful for
investigating the interactions between host genetics and the gut
microbiome in substance use. For example, C57BL/6 (B6) mice
consume sufficient alcohol levels to mimic binge-like drinking
episodes, making this strain a popular choice for modeling
binge alcohol intake (Thiele et al., 2014). Further work in this
model strain investigates links between alcohol consumption,
the gut microbiota, host gene expression, and drinking-related
phenotypes. Furthermore, rodent models of selectively inbred
“high drinkers” have been proposed for the use of screening
drugs aimed at reducing binge-like drinking behaviors (Crabbe
et al., 2017). Using single or selectively inbred strains effectively
isolates environmental variables of interest for experimentation
by controlling for genetic variation in the host. Considering
the complex diversity of the microbiota, isolating the microbial
effects while controlling for host genetics is prudent. Despite
the utility of inbred strains in isolating environmental effects,
this method does not fully consider both the genetic and
environmental complexity of SUD in humans, underpinning the
critical issue of translatability of rodent models.
DIVERSITY OUTBRED MOUSE MODELS
Much effort has been placed on developing recombinant-inbred
mouse strains to capture greater genetic diversity in strains
that are more applicable to complex disorders such as SUD
in humans. In 2004, a large multi-institutional initiative led to
the creation of the collaborative cross (CC) strains by crossing
among a set of eight mouse strains which represent >90% of the
genetic diversity of Mus musculus and its subspecies (Threadgill
et al., 2011). Because CC mice originate from founder strains
with defined genomes, this panel provides a high degree of
genetic diversity that can be accurately mapped with genotyping
techniques (Srivastava et al., 2017). Expanding further on
the CC mouse panel are the diversity outbred (DO) strains,
which provide even greater genetic and phenotypic diversity
by outbreeding, producing unique individual heterozygous mice
(Churchill et al., 2012).
There are numerous advantages to utilizing DO mice for
mapping phenotypic traits to host genotype. Because they
originate from the same founder strains as the CC panel, their
genomes are well defined and suited for fine-detail trait mapping
(Svenson et al., 2012). Furthermore, DO mice traits can be
recovered from inbred CC lines to test for allelic effects. Research
into benzene toxicity in DO mice revealed that harnessing
this genetic heterogeneity in the mouse better reflected the
diverse reactions to benzene exposure seen in humans (French
et al., 2015). Efforts using heterogeneous stock (HS) mice, with
similar genetic backgrounds as DO mice, have correlated genes
with sex-specific ethanol preference and chronic consumption
phenotypes, and similar results have been corroborated in DO
mice (Hitzemann et al., 2020). In the context of SUD, DO
mice may be used to study the interaction between host genes,
the environment (i.e., microbiome), and phenotypic differences
between strains that reflect similar genetic diversity in humans.
REPRODUCIBILITY THROUGH A
CONTROLLED ENVIRONMENT
Despite considerable effort, reproducibility in microbiome
research using animal models remains challenging. Careful
considerations must be made when studying the relationship
between genetics, phenotype, and the microbiome in an animal.
Microbiome differences in mice can be seen based on external
factors such as vendor, environmental and facility conditions, and
co-housing with other mice (Justice and Dhillon, 2016). When
controlling for genetics by using inbred strains, mouse-to-mouse
variation in microbiome composition is observed. A consistent
methodology plays a crucial role in the reproducibility of
microbiome research in animals, as circadian rhythm can also
have confounding effects for sampling at different times of
the day (Thaiss et al., 2014). In order to reduce confounding
individual variation of the microbiota, strategies for the rotation
of mice and mixing of bedding may be used so that all
mice in the experiment are normalized to the same common
microbiota. Furthermore, greater reproducibility can be achieved
by defining a standard microbiota composition for a given
model or experiment (Witjes et al., 2020). Thus, experimental
replication is more likely to be achieved by knowing the target
microbiota important for obtaining similar outcomes.
Though defining a normal microbiota for an experiment
or model organism may lead to a greater likelihood of
reproducibility, it raises the question of translatability since a
standardized microbiome is not realistic in humans. Here the
concept of increased reproducibility is at odds with the fact that
human disorders such as SUD are not simply defined systems.
Just as genetically diverse DO mice better reflect the natural
heterogeneity seen in humans, so too is there value in assessing
natural variation in the microbiome. The advent of “wildlings”
by implanting lab-strain mouse embryos into wild mice provides
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a useful tool for studying a more naturally derived microbiome
in an effort to enhance translatability (Rosshart et al., 2019).
Ultimately, the choice to standardize and how will depend on the
experimental question; whether there is a necessity to study the
full breadth of genetic and microbial heterogeneity such as that
in humans, to discover interactions between host and microbe,
or to isolate as best as possible specific genetic and environmental
factors for studying direct effects.
DISCUSSION
Addiction and substance use research has seen renewed
enthusiasm with a focus on the innate gut microbiota. Numerous
studies have proposed a connection between the gut microbiota
and the CNS via the gut–brain axis, providing a mechanism
by which these microbes influence the host. Often drug use
is associated with dysbiosis of the gut microbiome, and these
changes may be critical to the establishment and maintenance
of addiction by altering signals between the gut and the brain.
Thus, a probiotic intervention has garnered much interest as
a novel form of therapy for SUD. Recent evidence shows
promising effects of probiotics in treating other mental disorders,
including anxiety and depression, both of which are often co-
morbid with SUD (Abildgaard et al., 2017; Hadizadeh et al.,
2019; Kim and Kim, 2019; Liu et al., 2020). Fecal microbial
transplant is also an area of intense research. Studies in mice
have shown that transplantation of fecal microbiota of individuals
diagnosed with AUD leads to altered social and anxiety behaviors
and increased preference toward alcohol (Zhao et al., 2020).
Reciprocally, transplantation of microbiota from healthy donors
reduced anxiety and depressive behaviors in mice exposed to
alcohol (Xu et al., 2018). More research is needed to validate
the effects of FMT for other addictive substances and whether
dysbiosis perpetuates the chronic nature of addiction. Future
work will focus on untangling the mechanisms of gut microbiota
modulation on the host addiction behaviors to identify target
pathways and functions for potential probiotic therapeutics, such
as those focused on SCFA production.
Gut microbiome dysbiosis is evident after chronic and acute
substance use. However, more research is needed into whether
the gut microbiome may also serve as a source of environmental
risk for the development of SUD and addiction or be used as
a predictor of future SUD. Furthermore, interactions between
host genetics and gut microbiota deserve greater attention.
Recent evidence has suggested that host genetics can have strong
effects on the composition and function of the gut microbiome
(Goodrich et al., 2014; Abildgaard et al., 2017; Kim and Kim,
2019; Korach-Rechtman et al., 2019; Liu et al., 2020). Using
animal models from diverse genetic backgrounds will pave the
way toward understanding complex interactions between genetic
traits and the microbiota, especially given that genetically diverse
mice respond differently to probiotic interventions (McVey
Neufeld et al., 2018). Lastly, researchers must consider the
balance between the reproducibility of using inbred mouse
strains to test specific hypotheses versus the translatability of
genetically diverse mice, as both methods will be critical to not
only bolstering our understanding of the microbiome in SUD and
addiction but also its applicability to a diverse human population.
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